- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04968002
Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer: A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Gang Shen, master
- Phone Number: +86 571 87783641.
- Email: 2198022@zju.edu.cn
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- 2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
-
Contact:
- Gang Shen, master
- Phone Number: +86 571 87783641.
- Email: 2198022@zju.edu.cn
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:1. Age: 18-75 years old, male or female;
2. Non small cell lung cancer was diagnosed by imaging, histopathology or cytology
The resectable clinical stage assessed by the investigators was stage IIA - IIIA (according to AJCC)
TNM staging, 8th Edition);
3. ECoG PS score: 0-1;
4. According to the RECIST version 1.1 evaluation standard, at least one image can be measured
The lesions were measured;
5. There was no operation contraindication in preoperative organ function examination;
6. The laboratory examination indexes meet the requirements:
7. No previous treatment for NSCLC, including surgery and chemotherapy
Therapy, radiotherapy, targeted therapy, hormone or immunotherapy, etc;
8. Women of childbearing age agreed to use contraception during the study and within 6 months after the end of the study; study
The serum or urine pregnancy test was negative in the first seven days, and the patients were not in lactation
9. The subjects can understand the research situation and sign the informed consent voluntarily.
-
Exclusion Criteria: 1. Have received any treatment including chemotherapy in the past
Or radiotherapy;
2. The tumor has invaded important blood vessels or the tumor is in the treatment stage according to the judgment of the researcher
There is a high possibility of invading important blood vessels and causing massive hemorrhage;
3. Known EGFR mutation or ALK gene translocation;
4. There are locally advanced unresectable diseases and metastatic diseases;
5. She had been suffering from the need to use corticosteroids (prednisolone) in 14 days before randomization
Daily dose of nisone or equivalent (10 mg) or other immunosuppressive drugs
Any disease requiring systemic treatment. Local replacement steroids are permitted
(daily dose ≤ 10 mg of prednisone or equivalent) and prescription corticosteroids
Short term (≤ 7 days) prophylactic use of alcohol or for the treatment of non autoimmune.
Any active autoimmune disease or history of autoimmunity;
6. Active autoimmune diseases or autoimmune diseases that may recur
History. Admission of well controlled type I diabetes and hormone replacement therapy are allowed.
Hypothyroidism, well controlled celiac disease, and no need for complete treatment
Skin diseases (such as vitiligo, psoriasis or alopecia) treated by the body or not
Due to the absence of recurrence of the disease is not expected.
7. Interstitial lung disease, non infectious pneumonia or poorly controlled diseases (including pulmonary fibrosis)
History of vitamin C, acute lung disease, etc.
8. active hepatitis B (defined as screening hepatitis B virus surface antigen [HBsAg])
The results were positive and HBV-DNA was detected. The detection value was higher than that in the study
Upper limit of normal value of cardiology laboratory) or hepatitis C (defined as screening hepatitis C virus table)
The subjects with positive results of hcsab and HCV-RNA;
9. Known human immunodeficiency virus (HIV) infection (known HIV antibody positive);
10. Inoculate live vaccine within 30 days before the first administration. Including but not limited to the following:
Mumps, rubella, measles, varicella / herpes zoster (varicella), yellow fever
Rabies, BCG and typhoid vaccine (inactivated virus vaccine allowed);
11. Suffering from uncontrolled clinical symptoms or diseases of the heart;
12. Long term antiplatelet therapy is needed;
13. Those who are allergic to any drug in this program;
14. Pregnant or lactating women;
15. According to the judgment of the researcher, the subjects may confuse the test results and interfere
It is not in the best interests of the subjects to participate in the whole trial
A history or current evidence of any disease, treatment, or laboratory abnormality
It's a good idea.
16. Active bleeding.
Exclusion criterion:
- Ever received any treatment including chemotherapy or radiotherapy in the past;
- The tumor has invaded important blood vessels. There is a high possibility of invading important blood vessels and causing massive hemorrhage if the tumor is in the treatment stage process according to the judgment of the researcher;
- EGFR mutation or ALK gene translocation;
- There are locally advanced unresectable diseases and metastatic diseases;
- Patients had been suffering from the need to use corticosteroids (prednisolone) in 14 days before randomization grouping. Daily dose of nisone or equivalent (10 mg) or other immunosuppressive drugs. Any active autoimmune disease or history of autoimmunity;
- Active autoimmune diseases or autoimmune diseases that may recur
- Interstitial lung disease, non infectious pneumonia or poorly controlled diseases (including pulmonary fibrosis) etc.
- active hepatitis B (defined as screening hepatitis B virus surface antigen [HBsAg]). And the results were positive and HBV-DNA was detected. The detection value was higher than that in the study upper limit of normal value of cardiology laboratory) or hepatitis C (defined as screening hepatitis C virus table and the subjects with positive results of hcsab and HCV-RNA;
- Known human immunodeficiency virus (HIV) infection (known HIV antibody positive);
- Inoculated live vaccine within 30 days before the first administration. Including but not limited to the following: Mumps, rubella, measles, varicella / herpes zoster (varicella), yellow fever Rabies, BCG and typhoid vaccine (inactivated virus vaccine allowed);
- Suffering from uncontrolled clinical symptoms or diseases of the heart;
- Long term antiplatelet therapy is needed;
- Those who are allergic to any drug in this program;
- Pregnant or lactating women.;
- According to the judgment of the researcher, the subjects may confuse and interfere the test results. It is not in the best interests of the subjects to participate in the whole trial.
- Active bleeding patients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Preoperative neoadjuvant therapy for patients with stage IIa-IIIa non-small cell lung cancer.
No EGFR mutation or ALK gene translocation was found in the untreated patients with NSCLC stage IIa-IIIb diagnosed by imaging, histopathology or cytology.
After informed consent is signed by the patients.
The patients were treated according to the protocols.
|
The patients with stage IIa-IIIa non-small cell lung cancer are treated with pablizumab combined with apatinib and neoadjuvant chemotherapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The main pathological response rate
Time Frame: through surgical treatment completion, an average of 4 months
|
After neoadjuvant therapy, the residual tumor was observed under microscope with a result of the proportion of tumor cells was less than or equal to 10%.
|
through surgical treatment completion, an average of 4 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Protein Kinase Inhibitors
- Apatinib
Other Study ID Numbers
- 2021-0309
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-small Cell Lung Cancer
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of California, San FranciscoAstraZenecaActive, not recruitingStage IIIA Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Cancer | Stage IB Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Cancer | Stage IIB Non-Small Cell Lung CancerUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
AIO-Studien-gGmbHBristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaboratorsRecruitingSmall-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage IIGermany
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
-
Alexander ChiNot yet recruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Carcinoma | Non-small Cell Lung Cancer Stage IIChina
-
National Cancer Institute (NCI)Not yet recruitingStage IIIA Non-small Cell Lung Cancer | Stage IA Non-small Cell Lung Cancer | Stage IB Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerCanada
-
Karen KellyBristol-Myers Squibb; National Cancer Institute (NCI); TransgeneCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung CancerUnited States
-
Stanford UniversityAstraZenecaRecruitingNon-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage IIUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IIA Non-small Cell Lung Cancer | Stage IIB Non-small Cell Lung CancerUnited States
Clinical Trials on pablizumab combined with apatinib and neoadjuvant chemotherapy
-
Tongji HospitalNational Natural Science Foundation of ChinaRecruitingEsophageal Squamous Cell Carcinoma | Neoadjuvant TherapiesChina
-
Sichuan Cancer Hospital and Research InstituteRecruiting
-
Second Affiliated Hospital, School of Medicine,...Active, not recruitingEfficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) HNSCCChina
-
Guoxin LiNot yet recruiting
-
Qilu Pharmaceutical Co., Ltd.UnknownNon-small-cell Lung CancerChina
-
University Hospital, RouenInstitut Curie; APHPRecruitingBladder Cancer | Chemotherapy EffectFrance
-
Yongyi ZengNot yet recruitingHepatocellular Carcinoma
-
Shandong Cancer Hospital and InstituteRecruitingAdvanced Esophageal Squamous Cell CancerChina
-
University Hospital, RouenInstitut CurieActive, not recruitingBladder Cancer | Genomic InstabilityFrance
-
Auxilio Mutuo Cancer CenterSanofiUnknown